Under one in 10 patients who could benefit from obesity jabs including Wegovy have access to them, states the global health agency as it issues its first advice on the drugs.
Given in excess of 1,000,000,000 individuals worldwide currently living with obesity, it is calling for increased and just access to these injectable treatments.
Per forecasts, in excess of 2,000,000,000 will be living with obesity by 2030 unless action is taken.
"Our new guidance affirms that obesity is a lifelong illness that can be managed with comprehensive and lifelong care," said its chief Tedros Adhanom Ghebreyesus.
Significant expense, constrained manufacturing, and distribution challenges are major obstacles to universal availability to the jabs that can aid individuals in losing substantial body mass, says the organization.
GLP-1 Therapy Scarcity
Despite the present most optimistic case, the production of these medications would only suffice for approximately 100 million people – fewer than 10% of the global need, per the health organization.
The advice calls on governments and firms to increase availability, by measures such as voluntary licensing.
The intellectual property rights on the active ingredient – the main ingredient of a leading brand – is scheduled to end in multiple nations in 2026.
The Way Obesity Drugs Operate
These medications mimick a body's own hormone to delay gastric emptying, reduce hunger and increase feelings of fullness so users eat less.
Patients typically start to lose weight in the initial weeks of starting on the once-weekly jabs.
Evidence indicates people may see weight return a year later of stopping the medication, when their usual food cravings return.
Being overweight or obese increases your likelihood for experiencing diseases, including type 2 diabetes, cardiovascular issues, brain attack, and certain cancers.
Obesity affects people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, per the WHO.
